Atabecestat, a potent brain-penetrable inhibitor of BACE1 activity that reduces CSF amyloid beta (Aβ), was developed for oral treatment for Alzheimer’s disease (AD). The gene discussed is BACE1; the disease is early-onset autosomal dominant Alzheimer disease.